Alimentary Canal

Barium Swallows

Colorectal Cancer

Digestive Oncology

Endocrine Disorders


Is It Necessary To Continue Oral Antiviral Treatment For Chronic Hepatitis B Virus Infection?


Cheng Lee Yi

Department of Gastroenterology and Hepatology, Catholic Universityof Daegu School of Medicine, Korea

Correspondence to Author:  Cheng Lee Yi


NAs, which reduce viral load, HBeAg seroconversion, and in certain cases, HBsAg seroconversion, have improved patient prognosis. The duration and end point of NA therapy, on the other hand, are still up for debate. HBeAg seroconversion and undetectable HBV DNA status are maintained for at least 6-12 months for HBeAg-positive patients, and undetectable HBV DNA status on three separate occasions 6 months apart for HBeAg-negative patients if they have been treated for at least 2 years, according to current international guidelines. The long-term viability of NA, particularly after stopping therapy, is unknown. If a persistent serological and/or virological response fails and a high off-treatment virological relapse develops, a proportion of patients who cease NA medication after HBeAg seroconversion may require retreatment.

seroconversion, durability, relapse


Cheng Lee Yi. Is It Necessary to Continue Oral Antiviral Treatment for Chronic Hepatitis B Virus Infection?. Japanese Journal of Gastroenterology 2023.

Journal Info

  • Journal Name: Japanese Journal of Gastroenterology
  • Impact Factor: 2.709**
  • ISSN: 2832-4870
  • DOI: 10.52338/jjogastro
  • Short Name: JJOGASTRO
  • Acceptance rate: 55%
  • Volume: 4 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days


  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal


  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility